Literature DB >> 3258364

Imbalances in T cell subpopulations in human gliomas.

M K Bhondeley1, R D Mehra, N K Mehra, A K Mohapatra, P N Tandon, S Roy, V Bijlani.   

Abstract

The quantitation of cells bearing CD3, CD4, CD8, and B cell phenotypic markers, as well as an estimation of serum immunoglobulin (Ig)G, IgA, and IgM, was carried out in a group of 39 glioma patients with different grades of malignancy. The findings were compared with those obtained from 21 normal healthy control subjects. The analysis revealed a significant decrease both in the absolute numbers and in the percentages of circulating CD3+ (p less than 0.001) and CD4+ (p less than 0.001) cells, while the CD8+ and Pan B+ cells remained within the normal range irrespective of the type and grade of tumor. The CD4+:CD8+ ratio was significantly decreased in all categories of patients. The CD4 lymphopenia was also evident in 10 patients who had no history of previous immunosuppressive drug therapy (steroids and anticonvulsants) until the commencement of the study. The Ig levels were within the normal range in patients with malignant astrocytoma and glioblastoma multiforme, whereas a three- and fourfold increase in the IgM level was observed in patients with astrocytoma. It is suggested that T cell lymphopenia in glioma patients could mainly be due to a selective depletion of CD4+ cells and that it occurs principally as a reaction to the tumor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258364     DOI: 10.3171/jns.1988.68.4.0589

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  12 in total

1.  Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.

Authors:  C A Kruse; K O Lillehei; D H Mitchell; B Kleinschmidt-DeMasters; D Bellgrau
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

3.  Immunohistochemical study of IOT-10 natural killer cells in brain metastases.

Authors:  J Vaquero; S Coca; J Escandón; R Magallón; R Martínez
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

4.  Immunologic status in children with brain tumors and the effect of therapy.

Authors:  R Kebudi; I Ayan; E Darendeliler; L Ağaoğlu; S Ekmekçioğlu; T Yağci; S Pişkin; N Bilge
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Allogeneic tumor-specific cytotoxic T lymphocytes.

Authors:  J M Redd; A C Lagarde; C A Kruse; D Bellgrau
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Peri-operative changes of cellular and humoral components of immunity with brain tumour surgery.

Authors:  W A Dauch; D Krex; J Heymanns; B Zeithammer; B L Bauer
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery.

Authors:  Olesja Fornara; Jenny Odeberg; Nina Wolmer Solberg; Charlotte Tammik; Petra Skarman; Inti Peredo; Giuseppe Stragliotto; Afsar Rahbar; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

Review 8.  Recent developments on immunotherapy for brain cancer.

Authors:  Derek A Wainwright; Pragati Nigam; Bart Thaci; Mahua Dey; Maciej S Lesniak
Journal:  Expert Opin Emerg Drugs       Date:  2012-04-25       Impact factor: 4.191

9.  Glioma Indian scenario: Is there a human leucocyte antigen association?

Authors:  U Shankarkumar; B Sridharan
Journal:  J Nat Sci Biol Med       Date:  2011-07

10.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.